Silver Book Fact

Pregalbin, an antiepileptic drug, produced around a 32% pain reduction (a significant reduction) at week 16 versus around 20% for placebo, in patients with neuropathic pain due to spinal cord injury.

Cardenas, Diana D, Edward C Nieshoff, Kota Suda, Shin-ichi Goto, Luis Sanin, Takehiko Kaneko, Jonathan Sporn, Bruce Parsons, Matt Soulsby, Ruoyong Yang, Ed Whalen, Joseph M Scavone, Makota M Suzuki, and Lloyd E Knapp. A Randomized Trial of Pregabalin in Patients with Neuropathic Pain due to Spinal Cord Injury. Neurology. 2013; 80(6): 533-9. http://www.neurology.org/content/early/2013/01/23/WNL.0b013e318281546b.abstract

Reference

Title
A Randomized Trial of Pregabalin in Patients with Neuropathic Pain due to Spinal Cord Injury
Publication
Neurology
Publication Date
2013
Authors
Cardenas, Diana D, Edward C Nieshoff, Kota Suda, Shin-ichi Goto, Luis Sanin, Takehiko Kaneko, Jonathan Sporn, Bruce Parsons, Matt Soulsby, Ruoyong Yang, Ed Whalen, Joseph M Scavone, Makota M Suzuki, and Lloyd E Knapp
Volume & Issue
Volume 80, Issue 6
Pages
533-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A meta-analysis of pscychological interventions for chronic low back pain found small but statistically significant effects for all interventions for as long as 5 years.  
  • Topical capsaicin was found in a meta-analysis to provide a degree of pain relief to some patients with painful neuropathic conditions.  
  • The combination of information for neuroimaging and circulatory biomarkers could improve both the sensitivity and specificity of pain diagnosis and thereby improve treatment.  
  • Nerve growth factor (NGF) has been found to be a major mediator of inflammatory and neuropathic pain and provides a new therapeutic target.  
  • An oral cannabinoid was found effective in relieving diabetic peripheral neuropathic pain symptoms and improving disturbed sleep, quality of life, and overall patient status.